IntelGenx Corp. (IGX) Inks Commercialization Agreement with RedHill Bipharma for Migraine Relief Treatment
IntelGenx Corp. has secured an agreement with RedHill Biopharma Ltd., a privately held pharmaceutical company, in which RedHill will co-develop and license IntelGenx’s first oral thin-film migraine relief product based upon the company’s proprietary VersaFilm technology. In the fourth quarter of 2009, IntelGenx released data suggesting VersaFilm as a product that is bioequivalent to a leading branded anti-migraine therapies. "We are excited to have concluded our first, of what we believe to be many future, thin-film partnerships," Dr. Horst G. Zerbe, president and CEO of IntelGenx stated in the press release. "This partnership will help accelerate the development of this…